BioAge Labs price target raised to $23 from $12 at Morgan Stanley

Morgan Stanley raised the firm’s price target on BioAge Labs (BIOA) to $23 from $12 and keeps an Equal Weight rating on the shares. Early Phase 1 BGE-102 data indicate robust activity, says the analyst, who is updating the firm’s model to reflect “best-in-class potential” of BGE-102 while looking for confirmation in Phase 2a results due later this year.